10x Genomics Q3 2026 net loss narrows 29% to $19.43 million
TXG•10x Genomics' third-quarter net loss narrowed 29% year over year to $19.4 million, while revenue rose to $150.7 million. The company raised its 2026 revenue guidance to $625 million–$635 million from $610 million–$630 million.
1. Quarterly results and outlook
10x Genomics reported a third-quarter 2026 net loss of $19.4 million, down 29% year over year, and revenue of $150.7 million. Gross margin rose 8 percentage points to 75%, primarily due to lower inventory write-downs and product mix changes. Global commercial shipments of Atera began, and the company introduced its Sentira cloud analysis platform. Full-year 2026 revenue guidance increased to $625 million–$635 million from $610 million–$630 million.
